Dynamic population changes in mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1724-1733

  Sun, Gang ^a   Luo, Tao ^a   Yang, Chongguang ^a   Dong, Xinran ^b   Li, Jing ^c   Zhu, Yongqiang ^d   Zheng, Huajun ^d   Tian, Weidong ^b   Wang, Shengyue ^d   Barry, Clifton E ^e   Mei, Jian ^c   Gao, Qian ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Municipal Center for Disease Control and Prevention   (China)

^d CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL MUTATION; CONTROLLED STUDY; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION DYNAMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; GENOME, BACTERIAL; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84869066832     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis601     Document Type: Article

References (50)

1. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011; 66:1417-30.
2. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6:e1000002.
3. Böttger EC, Springer B, Pletschette M, Sander P. Fitness of antibioticresistant microorganisms and compensatory mutations. Nat Med 1998; 4:1343-4.
4. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312:1944-6.
5. Böttger EC, Springer B. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 2008; 167:141-8.
6. Mariam SH, Werngren J, Aronsson J, Hoffner S, Andersson DI. Dynamics of antibiotic resistant Mycobacterium tuberculosis during longterm infection and antibiotic treatment. PLoS ONE 2011; 6:e21147.
7. Meacci F, Orru G, Iona E, et al. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol 2005; 43:3114-20.
8. Rinder H, Mieskes KT, Loscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2001; 5:339-45.
9. Chakravorty S, Aladegbami B, Thoms K, et al. Rapid detection of fluoroquinolone- resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol 2011; 49:932-40.
10. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767-72.
11. Post FA, Willcox PA, Mathema B, et al. Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug- resistant tuberculosis. J Infect Dis 2004; 190:99.
12. Sander P, Springer B, Prammananan T, et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002; 46:1204-11.
13. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77:830-40.
14. Sherman DR, Mdluli K, Hickey MJ, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272:1641-3.
15. Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2011; 44:106-10.
16. Brockhurst MA, Colegrave N, Rozen DE. Next-generation sequencing as a tool to study microbial evolution. Mol Ecol 2011; 20:972-80.
17. Barrick JE, Lenski RE. Genome-wide mutational diversity in an evolving population of Escherichia coli. Cold Spring Harb Symp Quant Biol 2009; 74:119-29.
18. Zagordi O, Klein R, Däumer M, Beerenwinkel N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res 2010; 38:7400-9.
19. Bull RA, Luciani F, McElroy K, et al. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog 2011; 7:e1002243.
20. Ioerger TR, Feng Y, Chen X, et al. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 2010; 11:670.
21. Ioerger TR, Koo S, No EG, et al. Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS ONE 2009; 4:e7778.
22. Schurch AC, Kremer K, Kiers A, et al. The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol 2010; 10:108-14.
23. Saunders NJ, Trivedi UH, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect 2011; 62:212-7.
24. Zhang L, Chen J, Shen X, et al. Highly polymorphic variable-number tandem repeats loci for differentiating Beijing genotype strains of Mycobacterium tuberculosis in Shanghai, China. FEMS Microbiol Lett 2008; 282:22-31.
25. Larsen MH, Biermann K, Tandberg S, Hsu T, Jacobs WR Jr. Genetic manipulation of Mycobacterium tuberculosis. Curr Protoc Microbiol 2007; 6:10A.2.
26. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754-60.
27. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537-44.
28. Zhang Y, Chen C, Liu J, et al. Complete genome sequences of Mycobacterium tuberculosis strains CCDC5079 and CCDC5080, which belong to the Beijing family. J Bacteriol 2011; 193:5591-2.
29. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43:491-8.
30. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25:2078-9.
31. Gagneux S, DeRiemer K, Van T, et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103:2869-73.
32. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996; 40:1053-6.
33. Leger M, Gavalda S, Guillet V, et al. The dual function of the Mycobacterium tuberculosis FadD32 required for mycolic acid biosynthesis. Chem Biol 2009; 16:510-9.
34. Trivedi OA, Arora P, Sridharan V, Tickoo R, Mohanty D, Gokhale RS. Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature 2004; 428:441-5.
35. Jenkins C, Bacon J, Allnutt J, et al. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother 2009; 63:1118-20.
36. Luo T, Zhao M, Li X, et al. Selection of mutations to detect multidrug- resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Chemother 2010; 54:1075-81.
37. Miralles R, Gerrish PJ, Moya A, Elena SF. Clonal interference and the evolution of RNA viruses. Science 1999; 285:1745.
38. Perfeito L, Fernandes L, Mota C, Gordo I. Adaptive mutations in bacteria: high rate and small effects. Science 2007; 317:813.
39. Kao KC, Sherlock G. Molecular characterization of clonal interference during adaptive evolution in asexual populations of Saccharomyces cerevisiae. Nat Genet 2008; 40:1499-504.
40. Bark C, Okwera A, Joloba M, et al. Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures. Tuberculosis 2011; 91:257-9.
41. Joloba M, Johnson J, Namale A, et al. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4:528-36.
42. Luciw PA, Oslund KL, Yang XW, et al. Stereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with Mycobacterium tuberculosis. Am J Physiol Lung Cell Mol Physiol 2011; 301:L731-8.
43. Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009; 77:4631-42.
44. Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43:482-6.
45. Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003; 71:7099-108.
46. Gerrish PJ, Lenski RE. The fate of competing beneficial mutations in an asexual population. Genetica 1998; 102:127-44.
47. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 48:2495.
48. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3:13-21.
49. Maisnier-Patin S, Andersson DI. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res Microbiol 2004; 155:360-9.
50. Motiwala AS, Dai Y, Jones-Lopez EC, et al. Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanisms. J Infect Dis 2010; 201:881-8.